NCIt definition : An engineered immunoglobulin M (IgM) bispecific antibody, with potential antineoplastic
activity. Imvotamab contains ten high affinity binding domains for the tumor-associated
antigen (TAA) CD20, and one binding domain for CD3, a T-cell surface antigen. Upon
administration, imvotamab binds to both T-cells and CD20-expressing B-lineage tumor
cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL)
response against the CD20-expressing tumor B-cells. Additionally, imvotamab induces
complement-dependent cytotoxicity (CDC) to a greater extent than anti-CD20/anti-CD3
IgG bispecific antibodies, thereby further enhancing the killing CD20-expressing tumor
cells. The extra binding units of imvotamab may bind cancer cells that express relatively
low amounts of CD20. Also, compared to IgG format bispecific T-cell engaging antibodies,
imvotamab appears to induce less cytokine release, which may reduce the risk of cytokine
release syndrome (CRS). CD20 is exclusively expressed on B-cells during most stages
of B-cell development and is often overexpressed in B-cell malignancies.;
Semantic type(s)